Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,208 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07383506RecruitingPhase 1
Study of a targeted pill for PIK3CA-mutated advanced cancers
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Scottsdale, ArizonaAges 18 years+ - NCT05204147RecruitingPhase 1
Radioactive antibody for CEA-making advanced cancers
This early-phase trial tests a radioactive antibody (Ac225-DOTA-M5A) that targets CEA, a protein found on many cancer cells. It's for people with advanced or metastatic cancers that produce CEA and who have no good standard treatment options left.
Duarte, CaliforniaAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07567846RecruitingPhase 1/Phase 2
GDC-1261 Safety and Activity in Advanced Prostate Cancer
This early-stage trial tests a new drug called GDC-1261 in men with advanced prostate cancer that has spread or gotten worse despite previous treatment. The study will look at whether the drug is safe and whether it helps slow or shrink the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT02102165Recruiting
Study samples from metastatic triple-negative breast cancer
This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.
BrusselsAges 18 years+ - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06551116Recruiting
Better HER2 testing for HER2-low breast cancer on Enhertu
This study looks at using a more detailed lab test to measure HER2 levels in people with HER2-low metastatic breast cancer who are starting or have just started treatment with Enhertu. The goal is to see if this test can help doctors better understand who might benefit from Enhertu.
San Francisco, CaliforniaAges 18 years+ - NCT06176534RecruitingPhase 2
Comparing two treatments for advanced breast cancer with low hormone receptor
This trial compares two treatment options for advanced breast cancer that has low hormone receptor levels and is HER2-negative. It tests whether a combination of chemotherapy followed by maintenance therapy works better than a CDK4/6 inhibitor combined with hormone therapy. This is for people who have not had chemotherapy for their advanced disease.
Zhengzhou, HenanAges 18 years+ - NCT05019690RecruitingPhase 1/Phase 2
Test drug combo for advanced triple-negative breast cancer
This trial studies how well apatinib plus albumin-bound paclitaxel works for advanced triple-negative breast cancer that has come back or spread. It may help shrink tumors and control the disease by targeting cancer growth in more than one way.
Fuzhou, FujianAges 18–75 - NCT03474822RecruitingPhase 1/Phase 2
Plasmodium immune treatment for breast and liver cancers
This early-phase study tests an immune-based treatment (using Plasmodium) for people with advanced breast cancer or advanced liver cancer. It aims to see whether the treatment is safe and whether it can help the body’s immune system fight the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06934538RecruitingPhase 1/Phase 2
Immunotherapy trial for advanced colorectal cancer
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Baltimore, MarylandAges 18–75 - NCT06908668RecruitingPhase 2
Adebrelimab plus chemo with or without radiation before breast cancer surgery
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
BeijingAges 18–70 - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT06839547Recruiting
Testing a new drug with radiation for advanced breast cancer brain tumors
This study looks at how well a new anti-tumor drug works when given along with radiation therapy for people whose advanced breast cancer has spread to the brain. It may help the radiation work better and control the cancer longer.
BeijingAges 18 years+ - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06771609RecruitingPhase 2
Immunotherapy plus low-dose chemo for advanced triple-negative breast cancer
This study tests a combination of an immunotherapy drug (PD-L1 inhibitor) with a special low-dose chemotherapy regimen (VEX) plus optional radiation for advanced triple-negative breast cancer. The goal is to see if this approach works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06776861Recruiting
Radiation plus immunotherapy for advanced breast cancer
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07540533RecruitingPhase 2
Toripalimab Plus Chemotherapy for Advanced HER2-Negative Breast Cancer
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
Zhengzhou, HenanAges 18 years+ - NCT07185997RecruitingPhase 3
Testing firmonertinib for a type of lung cancer with rare EGFR mutations
This trial tests a new drug, firmonertinib, against other EGFR inhibitors as a first treatment for advanced lung cancer that has specific rare EGFR mutations (PACC mutations). It is for people who haven't had other treatments for their advanced cancer.
Fullerton, CaliforniaAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Athens, GeorgiaAges 18 years+ - NCT04315233RecruitingPhase 1
Testing two drugs for hard-to-treat triple-negative breast and ovarian cancer
This Phase 1 trial tests ribociclib plus belinostat in people with metastatic triple-negative breast cancer or recurrent ovarian cancer. It also looks at your tumor’s genetics (from a fresh biopsy) to see who might respond better.
Salt Lake City, UtahAges 18 years+ - NCT05205200RecruitingPhase 2
Immune therapy for HR-positive, HER2-negative metastatic breast cancer
This Phase 2 trial studies an immune-based treatment for women with HR-positive and HER2-negative breast cancer that has spread or returned and can’t be cured with local treatment alone. The goal is to see whether the therapy can shrink tumors and improve disease control with acceptable safety.
ShanghaiAges 18–75 - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,208 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.